Kidney drug shows promise for heart health in small trial
NCT ID NCT04930549
First seen Feb 06, 2026 · Last updated May 21, 2026 · Updated 11 times
Summary
This study tested whether dapagliflozin, a drug used for diabetes, could improve blood vessel function in 32 adults with chronic kidney disease (CKD). Participants took the drug for 12 weeks, and researchers measured changes in artery health using ultrasound and other tests. The goal was to see if the drug could help protect blood vessels in people with CKD who do not have diabetes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL INSUFFICIENCY, CHRONIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department of Nephrology
Bois-Guillaume, 76230, France
-
Department of Pharmacology
Rouen, 76031, France
Conditions
Explore the condition pages connected to this study.